US4618600A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel polypeptide diuretic/vasodilators
Assignee: Scios LLC
•
Filing: 1984-04-19
•
Granted: 1986-10-21
•
Expires: 2004-04-19
Abstract
Abstract Methods and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering auriculin or a synthetic analog of auriculin to said host.
Inventors
- 👤 Lorin K. Johnson
- 👤 Steven A. Atlas
- 👤 John H. Laragh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 17:01
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/62; C12N15/625; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/58; C07K14/582; C12N15/63; C12N15/70; C12N15/79; C12N15/80; C12N15/81; C12N15/85; A; A61; A61K; A61K38/00; C07K2319/00; C07K2319/01; C07K2319/02; C07K2319/036; C07K2319/50; C07K2319/70; C07K2319/74; C07K2319/75
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
43 words
A polypeptide compound useful as a natriuretic, diuretic and vasorelaxant in mammals, said polypeptide compound comprising the formula: H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X where X is OH or Tyr-OH; and including such compound containing a disulfide bridge joining the cysteine residues, and the pharmacologically acceptable salts thereof.
Claim 2
Dependent Claim
43 words
A polypeptide compound useful as a natriuretic, diuretic and vasorelaxant in mammals, said polypeptide compound comprising the formula: H-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-X where X is OH or Tyr-OH; and including such compound containing a disulfide bridge joining the cysteine residues, and the pharmacologically acceptable salts thereof.
Claim 3
Dependent Claim
20 words
Antisera and antibodies which are capable of recognizing and specifically binding to immunoreactive polypeptides comprising the polypeptides of claim 1.
Claim 4
Dependent Claim
32 words
A pharmaceutical composition useful as a natriuretic, diuretic and vasorelaxant in mammals, comprising a polypeptide compound in accordance with claim 1 in a therapeutically effective amount, together with a physiologically suitable carrier.
Claim 5
Dependent Claim
29 words
A method for inducing natriuresis and diuresis in a mammalian host which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 1 or 3.
Claim 6
Dependent Claim
31 words
A method for inducing vasodilatation and blood pressure reduction in a mammalian host which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 2 or 3.
Claim 7
Dependent Claim
34 words
A method for modulating angiotensin-induced aldosterone release in a mammalian host in need of said modulation which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 2 or 3.
Claim 8
Dependent Claim
33 words
A method for inhibiting renin secretion in a mammalian host in need of said inhibition which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 2 or 3.
Claim 9
Dependent Claim
54 words
A method for the treatment of congestive heart failure, nephrotic syndrome, hepatic cirrhosis and other conditions characterized by chronic increased extracellular fluid volume and ineffective renal perfusion, in a mammalian host in need of said treatment which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 1 or 3.
Claim 10
Dependent Claim
34 words
A method for the treatment of hypertension in a mammalian host in need of said treatment which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 2 or 3.
Claim 11
Dependent Claim
47 words
A method for the treatment of renal failure which is characterized by ineffective renal perfusion or reduced glomerular filtration rate in a mammalian host in need of said treatment which comprises administering to said host a pharmaceutically effective amount of the polypeptides of claim 2 or 3.
References Cited (Backward Citations)
US4016258A
Cited
US4113711A
Cited
US4237046A
Cited
EP0116784A2
Cited
US4496544A
Cited
US4508712A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-20 | 1990-04-21 | 1990-10-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-20 | 1994-04-21 | 1994-10-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-20 | 1998-04-21 | 1998-10-21 | $7700.00 | Window Closed / Lapsed |